Russell Investments Group Ltd. grew its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 101.7% in the third quarter, Holdings Channel reports. The institutional investor owned 282,873 shares of the biopharmaceutical company’s stock after purchasing an additional 142,654 shares during the period. Russell Investments Group Ltd.’s holdings in Insmed were worth $32,446,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in the stock. Virginia Estate & Retirement Planning Advisors Inc. bought a new stake in shares of Insmed in the third quarter valued at about $29,000. SBI Securities Co. Ltd. boosted its holdings in Insmed by 69.4% during the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 143 shares in the last quarter. CX Institutional bought a new stake in Insmed in the third quarter valued at $46,000. Harbor Investment Advisory LLC bought a new stake in shares of Insmed in the 2nd quarter worth about $52,000. Finally, Heritage Family Offices LLP bought a new stake in Insmed during the third quarter worth about $60,000.
Insider Transactions at Insmed
In related news, Director David Brennan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director owned 39,238 shares in the company, valued at approximately $4,865,512. This represents a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.
Insmed Stock Performance
Insmed (NASDAQ:INSM – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The company’s revenue was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.75) EPS. Equities analysts expect that Insmed, Inc. will post -1.86 EPS for the current fiscal year.
Wall Street Analyst Weigh In
INSM has been the topic of several research analyst reports. Stifel Nicolaus set a $195.00 target price on Insmed in a report on Thursday, October 29th. Jefferies Financial Group reissued a “buy” rating and issued a $175.00 price target on shares of Insmed in a report on Thursday, August 6th. JPMorgan Chase & Co. dropped their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, August 10th. Raymond James Financial set a $173.00 target price on shares of Insmed in a research report on Tuesday, October 20th. Finally, Guggenheim lowered their price target on Insmed from $205.00 to $201.00 and set a “buy” rating for the company in a research note on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $196.52.
Read Our Latest Research Report on INSM
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
Recommended Stories
- Five stocks we like better than Insmed
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
